Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Zuclomiphene reduces moderate to severe hot flashes in men with prostate cancer on ADT

Jan. 15, 2020

Topline data presented from TRILOGY 1 study of CaPre

Jan. 14, 2020

BioMarin to initiate clinical testing of BMN-307 gene therapy

Jan. 14, 2020

MRAP2 is accessory after the fact for appetite regulation

Jan. 14, 2020

Entrada announces development of ENTR-501 for mitochondrial neurogastrointestinal encephalomyopathy

Jan. 10, 2020

Regeneron announces phase II data for garetosmab in fibrodysplasia ossificans progressiva

Jan. 10, 2020

Bone Biologics' rhNELL-1 growth factor promotes bone formation in preclinical study

Jan. 9, 2020

FDA clears Carmell's IND for pivotal study of BHA for open tibia fractures

Jan. 9, 2020

Topline data from pivotal phase II portion of the ACTION-Galactosemia study

Jan. 9, 2020

Hepcidin mimetic PTG-300 begins phase II study in hereditary hemochromatosis

Jan. 7, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III
BioWorld
Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc.,...